Compendio Revista Osteo 360-DEFINITIVA (Abr'20)

En resumen, los autores afirman que el progreso en
el campo de endotipos y fenotipos de OA es
importante para el diseño de tratamientos
efectivos, estratificados, tomando en cuenta el
impacto que la OA posee en el individuo y la
sociedad en el mundo entero.
REFERENCIAS
1.- Chaput JP, Klingenberg L, Astrup A, Sjödin AM. Modern sedentary activities promote overconsumption of food in our current obesogenic environment. Obes
Rev 2011; 12:e12–e20.
2.- Owens C, Conaghan PG. Improving joint pain and function in osteoarthritis. Practitioner 2016; 260:17–20.
3.- Deveza LA, Loeser RF. Is osteoarthritis one disease or a collection of many? Rheumatology 2018; 57:iv34–iv42.
4.- Loeser RF. Aging and osteoarthritis. Curr Opin Rheumatol 2011; 23:492 – 496.
5.- Sutton S, Clutterbuck A, Harris P, Gent T, Freeman S, Foster N, et al. The contribution of the synovium, synovial derived inflammatory cytokines and
neuropeptides to the pathogenesis of osteoarthritis. Vet J 2009; 179:10–24.
6.- Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010; 6:625 – 635.
7.- Poulet B, Beier F. Targeting oxidative stress to reduce osteoarthritis. Arthritis Res Ther 2016; 18:32.
8.- Henrotin Y, Sanchez C, Bay-Jensen AC, Mobasheri A. Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future
perspectives. Ann Phys Rehabil Med 2016; 59:145–148.
9.- Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, et al. OARSI FDA Osteoarthritis Biomarkers Working Group. Application of biomarkers in
the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2011 May;19(5):515-42. doi: 10.1016/j.joca.2010.08.019.
10.- Dell'Isola A, Allan R, Smith SL, Marreiros SS, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC
Musculoskelet Disord. 2016 Oct 12;17(1):425.
11.- Pepys MB, Hirsch eld GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805–1812.
12.- Greene MA, Loeser RF. Aging-related inflammation in osteoarthritis. Osteoarthr Cartil 2015; 23:1966 – 1971.
13.- Kjelgaard-Petersen C, Siebuhr AS, Christiansen T, Ladel C, Karsdal M, Bay-Jensen AC. Synovitis biomarkers: ex vivo characterization of three biomarkers for
identification of inflammatory osteoarthritis. Biomarkers 2015; 20: 547–556.
14.- Lotz M, Martel-Pelletier J, Christiansen C, Brandi ML, Bruyère O, Chapurlat R, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann
Rheum Dis 2013; 72:1756– 1763.
15.- Findlay DM, Kuliwaba JS. Bone-cartilage crosstalk: a conversation for understanding osteoarthritis. Bone Res 2016; 4:16028.
doi:10.1038/boneres.2016.28
16.- Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P,et al. Should subchondral bone turnover be targeted when treating
osteoarthritis? Osteoarthr Cartil 2008; 16:638– 646.
17.- Huebner JL, Bay-Jensen AC, Hu man KM, He Y, Leeming DJ, McDaniel GE, et al. Alpha C-telopeptide of type I collagen is associated with subchondral bone
turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis. Arthritis Rheumatol 2014; 66:2440–2449.
18.- Le Clanche S, Bonnefont-Rousselot D, Sari-Ali E, Rannou F, Borderie D. Inter-relations between osteoarthritis and metabolic syndrome: a common link?
Biochimie 2016; 121:238–252.
19.- Dell'Isola A, Steultjens M. Classification of patients with knee osteoarthritis in clinical phenotypes: data from the osteoarthritis initiative. PLoS One 2018;
13:e0191045.
20.- Van der Esch M, Knoop J, van der Leeden M, Roorda LD, Lems WF, Knol DL, Dekker J. Clinical phenotypes in patients with knee osteoarthritis: a study in the
Amsterdam osteoarthritis cohort. Osteoarthr Cartil 2015; 23:544– 549.
21.- Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860–867
22.- Saudek DM, Kay J. Advanced glycation endproducts and osteoarthritis. Curr Rheumatol Rep 2003; 5:33–40.
23.- Zhang W, Likhodii S, Zhang Y, et al. Classification of osteoarthritis phenotypes by meabolomics analysis. BMJ Open 2014; 4:e006286.
24.- Legrand C, Ahmed U, Anwar A, Rajpoot K, Pasha S, Lambert C, et al. Glycation marker glucosepane increases with the progression of osteoarthritis and
correlates with morphological and functional changes of cartilage in vivo. Arthritis Res Ther 2018; 20:131.
25.- Sell DR, Biemel KM, Reihl O, Lederer MO, Strauch CM, Monnier VM. Glucosepane is a major protein cross-link of the senescent human extracellular matrix.
Relationship with diabetes. J Biol Chem 2005; 280:12310–12315.
26.- Jeon OH, David N, Campisi J, Elissee JH. Senescent cells and osteoarthritis: a painful connection. J Clin Invest 2018; 128:1229–1237
OSTEO
360
50
Novedades en patología osteomioarticular